Assessment of different markers of bone resorption in postmenopausal osteoporotic women treated with pamidronate

References

• Eyre D R, Paz P M. Cross-linking in collagen and elastin. Ann Rev Biochem 1984; 53: 717–48
   PubMed Web of Science ®Google Scholar
• Delmas P D, Schlemmer A, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patient with vertebral osteoporosis. J Bone Min Res 1991; 6: 639–44
   PubMed Web of Science ®Google Scholar
• Eastell R, Colwell A, Hampton L, Reeve J. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res 1997; 12: 59–65
   PubMed Web of Science ®Google Scholar
• Robins S P, Black D, Paterson C R, Reid D M, Duncan A, Seibel M J. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest 1991; 21: 310–15
   PubMed Web of Science ®Google Scholar
• Eyre D R, Koob T J, Van Ness K P. Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Analyt Biochem 1984; 137: 380–8
   PubMed Web of Science ®Google Scholar
• Robins S P, Duncan A, Riggs B L. Direct measurements of free hydroxy-pyridinium crosslinks of collagen in urine as new markers of bone resorption. Proceedings on Osteoporosis; Copenhagen: Osteopress ADS, C Christiansen, A Johansen. 1990; 465–68
   Google Scholar
• Garnero P, Shih W J, Gineyts E, Karpf D B, Delmas P D. Comparison of new markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1696–700
   Google Scholar
• Seibel M J, Cosman F, Shen V, Gordon S, Dempster D W, Ratcliffe A, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Mineral Res 1993; 8: 887–9
   Google Scholar
• Gallacher S J, Fraser W D, Logue F C, Dryburgh F J, Cowan R A, Boyle I T, et al. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy. Calcif Tissue Int 1992; 51: 419–23
   Google Scholar
• Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas P D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Min Res 1995; 10: 641–9
   PubMed Web of Science ®Google Scholar
• Eyre R E. The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand 1995; 60(Suppl 266)166–70
   Google Scholar
• Kollerup G, Beck Jensen J-E, Thamsborg G, Hauge E, Melsen F, Sørensen O H. Correlation between bone histomorphometry and markers of bone formation and resorption in postmenopausal women. Bone 1995; 16(Suppl 1)112S
   Google Scholar
• Seyedin S M, Kung V T, Daniloff Y N, Heslev R P, Gomez B, Nielsen L A, et al. Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993; 5: 635–41
   Google Scholar
• Robins S P, Woitge H, Hesley R, Ju J, Seyedin S, Seibel M J. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994; 9: 1643–9
   PubMed Web of Science ®Google Scholar
• Fleich H. Diphosphonates: history and mechanism of action. Metab Bone Dis Relat Res 1981; 3: 279–87
   Google Scholar
• Valkema R, Vismans F JFE, Papapoulos S E, Pauwels E KJ, Bijvoet O LM. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with bisphosphonate. APD Bone Miner 1989; 5: 189–92
   Google Scholar
• Frijlink W B, Bijvoet O LM, TeVelde J, Heynen G. Treatment of Paget's disease with 3-amino-1-hydroxyprophylidene-1, 1-bisphonates (APD). Lancet 1987; 1: 799–803
   Google Scholar
• Mallmin H, Ljunghall S, Larsson K, Lindh E. Short-term effects of pamidronate on biochemical markers of bone metabolism in osteoporosis—a placebo-controlled dose-finding study. Upsala J Med Sci 1991; 96: 205–12
   Web of Science ®Google Scholar
• Kollerup G, Thamsborg G, Bhatia H, Sørensen O H. Quantitation of urinary hydroxypyridinium cross-links from collagen by high-performance liquid chromatography. Scan J Clin Lab Invest 1992; 52: 657–62
   PubMed Web of Science ®Google Scholar
• Kivirikko K I, Laitinen O, Prokop D J. Modification of a specific assay for hydroxyproline in urine. Analyt Biochem 1967; 19: 249–55
   PubMed Web of Science ®Google Scholar
• Harris S T, Gertz B J, Genant H K, Eyre D R, Survill T T, Ventura J N, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993; 76: 1399–406
   PubMed Web of Science ®Google Scholar
• Colwell A, Eastell R. Renal clearance of free and conjugated pyridinium crosslinks of collagen. J Bone Miner Res 1996; 11(Suppl 1)S192
   Google Scholar
• Naylor K E, Blumsohn A, Assiri A, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Calcif Tissue 1995; 5: 445, Int.
   Google Scholar
• Vasikaran S D, McCloskey E V, Kahn S, Kanis J A. Intra-individual variation in fasting urinary calcium- and hydroxyproline-creatinine ratios measured in metabolic bone clinic patients as both outpatients and inpatients. Ann Clin Biochem 1994; 31: 272–6
   PubMedGoogle Scholar
• Jensen J-EB, Sørensen H A, Kollerup G, Jensen L B, Sørensen O H. Biological variation of biochemical bone markers. Scand J Clin Invest 1994; 54(Suppl 219)36–9
   Google Scholar